We are live on ! Find out more
PBYI icon

Puma Biotechnology

163 hedge funds and large institutions have $2.27B invested in Puma Biotechnology in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 66 increasing their positions, 56 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

438% more call options, than puts

Call options by funds: $149M | Put options by funds: $27.6M

18% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 56

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1.4% less ownership

Funds ownership: 94.72%93.32% (-1.4%)

18% less funds holding

Funds holding: 198163 (-35)

36% less capital invested

Capital invested by funds: $3.55B → $2.27B (-$1.28B)

72% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 47

Holders
163
Holders Change
-35
Holders Change %
-17.68%
% of All Funds
4.54%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
13
Increased
66
Reduced
56
Closed
47
Calls
$149M
Puts
$27.6M
Net Calls
+$121M
Net Calls Change
+$122M

PBYI Hedge Fund Activity: Q3 2015 in Review

163 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2015, worth a combined $2.27B — down 36% from $3.55B a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of PBYI and 13 opened new positions — a net loss of 34 holders — while 56 trimmed existing stakes and 66 added.

The largest buyer was Point72 Asset Management, adding an estimated $45.9M. The largest seller was Capital Research Global Investors, cutting an estimated $82.4M.

  • 163 institutional investors held Puma Biotechnology (PBYI) as of Q3 2015, down from 198 in Q2 2015.
  • Funds reported $2.27B of Puma Biotechnology stock for Q3 2015, down 36% quarter-over-quarter.
  • 13 funds opened new Puma Biotechnology positions in Q3 2015 and 47 closed out, a net change of -34 holders.
  • The largest Puma Biotechnology buyer in Q3 2015 was Point72 Asset Management, an estimated $45.9M added.
  • The largest Puma Biotechnology seller in Q3 2015 was Capital Research Global Investors, an estimated $82.4M sold.

Based on aggregated 13F filings for Q3 2015.